Articles related to NEOADJUVANT TREATMENT

In cisplatin-eligible patients with muscle-invasive bladder cancer, perioperative durvalumab combined with standard chemotherapy demonstrated an 8% absolute improvement in event-free survival at 24 months compared to chemotherapy alone.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.

A phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab followed by surgery to adjuvant nivolumab alone in resectable stage III melanoma patients found a significantly higher event-free survival rate in the neoadjuvant group. This suggests that pre-surgical immunotherapy could lead to better patient outcomes.

Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.